Targeting Acute Inflammatory Anorectal Conditions

This medication is commonly used for symptomatic management in conditions involving inflammatory or irritative processes. The primary conditions it helps address include acute hemorrhoids (stages 1 and 2), proctitis, anal eczema, and superficial anal fissures, which are conditions presenting with localized discomfort. This medication is applied across domains where additional symptomatic support is needed, consistent with its known therapeutic profile. It may assist with easing the overall symptom load by targeting localized irritation and swelling, generally contributing to improved comfort during periods of heightened symptoms.

---

Relief from Sensory Symptoms and Clinical Support

The formulation is relevant for managing symptom clusters that may become intense or disruptive, specifically symptoms related to physical discomfort, such as localized pain, burning, and intense itching (pruritus). It is applied across domains where additional symptomatic support is needed, including during flare-ups of chronic disease or in pre- and postoperative care. This approach offers symptomatic relief that may help patients cope more steadily with symptom fluctuations. It supports patients during episodes of heightened discomfort. The medication is commonly used to help with symptoms that create noticeable functional strain.

Quick Fact: Relief for Combined Symptoms
Primary Focus	Inflammatory states and acute localized pain
Use Context	Episodic management and supportive clinical scenarios
Core Benefit	Contributes to easing the overall symptom load

Regulatory References

1. Indonesian Food and Drug Authority (BPOM) Assessment Report

Contraindications and Restrictions for Релиф Про

Релиф Про is not permitted for use in several populations, primarily defined by the presence of specific infections or known sensitivities according to regulatory documentation. Use is absolutely contraindicated if a patient has a known allergy (hypersensitivity) to Fluocortolone, Lidocaine, or any excipient. Furthermore, the medicine must not be applied if specific viral diseases (such as vaccinia or chickenpox) or tuberculous/syphilitic processes are present in the treatment area. Use is also prohibited if the patient has any untreated local bacterial or fungal infection.

These eligibility rules define who can safely use the drug under labeled conditions. Beyond the absolute contraindications, long-term continuous use is generally avoided in all populations, and a benefit-to-risk review is required for pregnant or lactating women.

Population Eligibility Status	Official Regulatory Stance
Not Recommended	Women in the first trimester of pregnancy.
Age-Related Caution	Long-term continuous therapy must be avoided in infants and children.
Conditional Use	Patients with severe hepatic or renal impairment require caution; treated infections require concurrent anti-infective therapy.

Interactions with other medicines and products

The official interaction profile for this rectal preparation is primarily structured around the potential systemic absorption of the Lidocaine Hydrochloride component, which may lead to documented pharmacodynamic interactions with specific cardiovascular and anesthetic agents.

Formal Restrictions and Additive Effects

The co-administration of this medicine is formally contraindicated outside of a hospital setting with Class III Anti-arrhythmic Drugs, such as amiodarone or sotalol. This restriction is documented in regulatory labeling due to the risk of additive cardiac effects resulting from the lidocaine component.

Furthermore, co-administration with other local anaesthetic agents or substances structurally related to amide-type anaesthetics, including Class IB Anti-arrhythmics, is cautioned against because the resulting toxic effects are additive. This requires regulatory understanding when the product is used alongside any agent that shares a similar action or toxic profile.

Population-Specific Constraint

The regulatory documentation notes a specific interaction constraint concerning patient populations with compromised liver function. Caution is required in patients with hepatic impairment. This is based on the official understanding that the clearance of the Lidocaine component may be reduced, potentially increasing systemic exposure and consequently heightening the risk of the documented additive toxic effects from interacting medicinal products.

No specific interactions with food, alcohol, dietary supplements, or herbal products are explicitly documented in the official prescribing information for this combined rectal preparation.

The pharmacological action of Релиф Про involves two distinct mechanistic domains that modulate both peripheral nociceptive signaling and the localized inflammatory cascade.

Genomic Suppression of the Inflammatory Cascade

The active ingredient Fluocortolone works by acting as an agonist for the Glucocorticoid Receptor (GR), a nuclear receptor found inside cells. The activated receptor complex alters gene transcription through transrepression of pro-inflammatory genes and transactivation of anti-inflammatory proteins, which ultimately reduces the production of inflammatory mediators like prostaglandins and leukotrienes. This genomic mechanism results in the sustained attenuation of the localized inflammatory cascade, decreasing tissue fluid accumulation (edema) and cellular infiltration.

Rapid Blockade of Nociceptive Signal Transmission

The mechanism of Lidocaine Hydrochloride provides immediate action by producing a reversible blockade of Voltage-Gated Sodium Channels ( Na v channels) on the membranes of peripheral sensory nerves. By preventing the necessary influx of Na^+ ions, Lidocaine inhibits the nerve's ability to depolarize and generate an action potential, effectively halting the transmission of localized sensory impulses. This non-genomic action results in the immediate inhibition of action potential generation and a corresponding interruption of localized sensory signaling.

Complementary Dual-Action Timing

The combination involves a functional synergy where the fast-kinetics, non-genomic channel blockade occurs rapidly, preceding the engagement of the slow-kinetics, genomic anti-inflammatory effect. This coordinated approach facilitates the simultaneous modulation of peripheral sensory signaling and the localized biological inflammatory response.

Instruction Map: How to use Релиф Про — Official Administration Guidelines

This map consolidates the administration protocols for the combined fluocortolone and lidocaine product.

Administration Scope	Details
Route of administration:	Topical and Rectal route only.
Dosing schedule:	One unit of the prescribed form (suppository or cream application) per use.
	Initial dosing is 2 to 3 applications daily, with the option for up to 4 applications on the first day in acute cases.
Timing in relation to meals:	Rectal application is not dependent on meal timing.
Preparation requirements:	The rectal cream requires the use of a specialized applicator for proper intra-rectal administration.
Age-group administration rules:	Product labeling does not typically detail specific dose adjustments for older adults or those with renal or hepatic impairment.
Missed-dose rules:	Guidance suggests avoiding doubling the next dose to compensate for a forgotten one.
Special procedural conditions:	Administration is recommended to occur after defecation to maximize local effect.

Instruction Classifications (High-Level)	Details
Administration method type:	Topical
Frequency pattern:	Multiple times per day (acute), reducing to once daily (maintenance).
Basis of instructions:	Standardized product labeling.
Use-context constraints:	Restricted to short-term use only, with continuous application generally limited to 7 days, though some protocols permit a maximum of four weeks.

Resulting Procedural Structure

Official step sequence:

• Administer the medication after a bowel movement.
• Initiate application at the higher frequency (e.g., two to three times per day).
• Reduce the frequency to a once-daily maintenance dose as symptoms improve.
• Discontinue use upon completion of the course, ensuring the maximum duration constraint is not exceeded.

Connection to the overall use protocol: A standardized, localized protocol defines the medication's appropriate usage. This structure mandates direct rectal delivery and a usage pattern that begins with frequent application and then transitions to a lower frequency. The fixed short-term duration is an essential principle governing the overall administration course.

Research Evidence / Overview of Studies for Релиф Про

This section outlines the structure of research and the types of studies that have examined the combination of fluocortolone and lidocaine (Релиф Про). This overview describes what researchers explored and what remains uncertain, without offering individual medical advice or making claims about guaranteed outcomes.

Evidence for Use in Acute Hemorrhoidal Disease

Research was conducted to explore how outcomes related to physical discomfort change over the observation period in clinical studies, including large, multicenter non-interventional cohort studies. These studies primarily included adult patients experiencing conditions characterized by fluctuating or episodic manifestations, such as acute hemorrhoidal flare-ups.

Outcomes monitored focused heavily on patient-reported outcomes describing perceived discomfort. Researchers used standardized scales to measure the severity of pain, burning, itching, and overall discomfort. Findings describe patterns observed in the studies related to the severity of acute hemorrhoidal symptoms across the short treatment period. However, comparative evidence (e.g., against a non-active control) is often lacking in the published research structure.

Evidence for Use in Other Anorectal Conditions (Proctitis and Fissures)

Research explored the combination in the context of managing symptoms in conditions involving periods of heightened symptoms such as proctitis and anal fissures. The research structure for these areas relies on the inclusion of components with established properties for localized numbing and investigating inflammatory states.

Evidence is limited for this specific fixed-dose combination targeting proctitis or anal fissure healing as a primary, dedicated research endpoint. The available research generally serves to provide context on symptom patterns, rather than detailed analysis on healing or specific disease progression. Subgroup findings are uncertain due to the sparse nature of dedicated trials for these indications.

️ Long-Term Studies and Follow-Up Duration

Long-term effects are not fully established because the primary studies supporting the combination generally was evaluated in settings focusing on acute episodes and follow-up durations were limited. Evidence provides insight into short-term changes but does not characterize the duration of a sustained response or recurrence rates over many months. Regulatory reviews generally note that data on the effects or safety profile beyond the initial short-term observation period remain insufficient.

Common questions about Релиф Про (FAQ)

Q: How long after starting treatment should I expect to see results?

According to the official product information for Релиф Про, symptomatic relief, such as a reduction in pain and discomfort, is often observed within a few days of starting treatment. Regulatory documents outline the recommended duration of use for the medicine.

Q: Can children use Релиф Про?

Regulatory documents state that the safety and effectiveness of Релиф Про have not been established for use in patients under 18 years of age. For this reason, official product information does not recommend this medicine for pediatric use.

Q: What should I do if I miss a dose?

Regulatory guidance addresses missed doses, stating application is suggested as soon as the dose is remembered. However, information indicates that if it is nearly time for the next application, the missed dose is typically skipped, and the regular schedule is continued. The labeling advises against applying a double amount to make up for a forgotten dose.

Q: Is it safe to use this product long-term?

Official product information advises that continuous use of Релиф Про should generally not exceed a period of four weeks. This limitation is established in the product information because one of the active ingredients is a corticosteroid.

Q: Does this medicine interact with blood pressure drugs?

According to the official product information, no formal clinical studies on systemic (whole-body) drug interactions have been conducted for Релиф Про. Therefore, data on specific interactions with blood pressure medications are not available in the official product information.

How to Store and Dispose of Релиф Про (Relief Pro)

The storage and disposal of Релиф Про must strictly follow the requirements defined in official regulatory labeling to maintain product quality and public safety.

Official Storage Requirements

Condition	Requirement (As Stated in Labeling)
Temperature	Must be stored at a temperature not exceeding 25°C.
Protection	Requires protection from light and must be kept in the original container or package.
Child Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be handled and discarded in accordance with local requirements. This standard instruction ensures proper environmental disposal of pharmaceutical waste.